Melinta Therapeutics, Inc. (NASDAQ:MLNT)

13.20
Delayed Data
As of Feb 23
 +0.30 / +2.33%
Today’s Change
10.25
Today|||52-Week Range
24.25
-16.46%
Year-to-Date

Five Year Financial Summary

Total Revenue

Cash & Short Term Investments

Cash From Operations

All Currency in US Dollars4 Year
Trend

2013

2014

2015

2016
Revenue and IncomeNet Revenues7.8M15.2M27.3M18.0M
 
 
 
 
 
Depreciation And Amortization39.6K76.3K69.2K51.0K
 
 
 
 
 
 
Operating ExpensesGross Income----------
General Expenses50.7M74.5M116.2M135.2M
 
 
 
 
 
Research And Development41.3M62.5M93.4M81.7M
 
 
 
 
 
Total Operating Expenses50.7M74.6M116.2M135.2M
 
 
 
 
 
 
Non-Operating ExpensesOperating Income-42.9M-59.4M-88.9M-117.2M
 
 
 
 
 
Extraordinary Credit--119.7K0.000.00
 
 
Extraordinary Charge-217.4K0.000.000.00
 
 
Interest Expense On Debt1.9M2.4M2.2M1.2M
 
 
 
 
 
 
Income Taxes, Minority Interest and Extra ItemsPre-Tax Income-45.0M-61.6M-91.1M-118.0M
 
 
 
 
 
Net Income-45.0M-61.6M-91.1M-118.0M
 
 
 
 
 
 
Shares To Calculate EPSShares To Calculate EPS5.9M6.8M8.7M10.1M
 
 
 
 
 
Shares To Calculate EPS Diluted5.9M6.8M8.7M10.1M
 
 
 
 
 
 
Earnings Per ShareEPS-$7.65-$9.05-$10.45-$11.70
 
 
 
 
 
EPS Diluted-$7.65-$9.05-$10.45-$11.70